Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $313000.0.

  • Theravance Biopharma's Other Non-Current Liabilities fell 9371.11% to $313000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $313000.0, marking a year-over-year decrease of 9371.11%. This contributed to the annual value of $1.9 million for FY2024, which is 9762.26% down from last year.
  • As of Q3 2025, Theravance Biopharma's Other Non-Current Liabilities stood at $313000.0, which was down 9371.11% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Other Non-Current Liabilities registered a high of $79.5 million during Q4 2023, and its lowest value of $313000.0 during Q3 2025.
  • Over the past 5 years, Theravance Biopharma's median Other Non-Current Liabilities value was $4.9 million (recorded in 2024), while the average stood at $18.3 million.
  • In the last 5 years, Theravance Biopharma's Other Non-Current Liabilities skyrocketed by 230321.96% in 2022 and then tumbled by 9762.26% in 2024.
  • Quarter analysis of 5 years shows Theravance Biopharma's Other Non-Current Liabilities stood at $75.0 million in 2021, then grew by 1.3% to $76.0 million in 2022, then grew by 4.61% to $79.5 million in 2023, then tumbled by 97.62% to $1.9 million in 2024, then tumbled by 83.44% to $313000.0 in 2025.
  • Its last three reported values are $313000.0 in Q3 2025, $1.5 million for Q2 2025, and $1.3 million during Q1 2025.